Search results for "Pharmacokinetic modeling"
showing 3 items of 3 documents
PET: Theoretical Background and Practical Aspects
2012
Positron emission tomography (PET) is a nuclear medicine imaging tool utilized for investigation of physiological processes in vivo. PET uses the decay characteristics of positron-emitting radionuclides which are produced in a cyclotron and then used to label compounds involved in physiological processes. Usually, the labeled compound—the tracer—is administered intravenously and distributed in the tissue. The radionuclide decays and the emitted photons are detected by the PET scanner. PET then offers the possibility to compute three-dimensional images of the biodistribution and kinetics of the regional radioactivity concentration. There are several options to analyze reconstructed PET image…
Magnetic resonance pharmacokinetic imaging clusterization of hepatocellular carcinomas as a means to grade tumor aggressiveness.
2012
Hepatocellular carcinoma (HCC) management takes into account clinical and radiological findings, such as tumor stage, hepatic functional status and clinical symptoms. It is necessary to evaluate the number, size and location of the lesions. However, lesion aggressiveness is not considered in this therapeutic workflow, although the biology and the growth rate of the lesions have an important impact on survival. The aim of this work was to establish if the quantitative pharmacokinetic assessment of dynamic contrast-enhanced magnetic resonance images of HCC can separate lesions with different microvascular properties and biological evolution. Forty five patients with HCC and dynamic contrast-e…
Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
2020
MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in vitro and in vivo in metastatic breast cancer mouse models. The aim of this study is to develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK-PD) model of MBQ-167 to predict tumor growth inhibition following intraperitoneal (IP) administration in mice bearing Triple Negative and HER2+ mammary tumors. PBPK and Simeoni tumor growth inhibition (TGI) models were developed using the Simcyp V19 Animal Simulator. Our developed PBPK framework adequately describes the time course of MBQ-167 in each of the mo…